Daily Bio News Summary — 2026-09-01: CAR-T Safety Crisis Shakes Autoimmune Pipeline as Novartis and BMS Halt Trials

The Monday Harvest: 38 Articles from Six Sources

Today’s biopharma news harvest pulled 38 articles across six sources, with Endpoints News leading (9 items) followed by Fierce Biotech (8) and Fierce Pharma (6). The dominant story is a safety crisis in CAR-T therapy for autoimmune disease—three patient deaths have prompted Novartis to halt its trials and Bristol Myers Squibb to pause its own programs. Against that backdrop, Roche signed a billion-dollar deal with China’s Simcere, GSK’s mRNA flu vaccine advanced to Phase 3, and the White House rolled out nine new most-favored-nation drug pricing deals.

CAR-T Safety Crisis: Three Deaths Trigger Trial Halts

The biggest story of the day—and potentially one of the most consequential of the year—comes from Endpoints News, Fierce Biotech, and BioSpace: three patients have died in autoimmune CAR-T trials, prompting Novartis to halt its studies and Bristol Myers Squibb to follow suit by pausing its own programs.

Endpoints reports that the deaths occurred across Novartis’ autoimmune CAR-T pipeline, raising questions about the safety profile of a modality that had been hailed as a potential cure for lupus, myasthenia gravis, and other autoimmune conditions. BioSpace notes that BMS paused its programs “after safety events,” suggesting the concern extends beyond a single company’s construct.

This is a significant setback for the CAR-T-for-autoimmunity movement, which had been building momentum after early clinical successes in lupus and scleroderma. The field will now await detailed safety analyses before trials can resume—expect regulatory scrutiny and investor caution in the near term.

Roche-Simcere: A $1.53B Bet on B-Cell Biology

Roche inked a major deal with China’s Simcere, paying $1.53 billion for rights to a B-cell-targeting antibody (Fierce Biotech). Separately, Roche signed a trispecific T cell engager pact with Simcere in another China deal (Endpoints News), signaling Roche’s deep commitment to Chinese biotech partnerships.

The B-cell antibody deal is the larger of the two and positions Roche to compete in the increasingly crowded autoimmune B-cell depletion space. The trispecific T cell engager adds a novel modality to Roche’s oncology pipeline. Together, these deals underscore a trend: Western pharma giants are turning to Chinese biotecks for differentiated assets at a time when domestic dealmaking is becoming more expensive.

GSK’s mRNA Flu Vaccine Advances to Phase 3

Three outlets (Fierce Biotech, Endpoints News, BioSpace) covered GSK’s announcement that its mRNA-based flu vaccine beat standard shots in trials, clearing the path to a Phase 3 program. Endpoints notes GSK plans to test a “newer formulation” in the pivotal study, while BioSpace frames it as part of a broader “resurgence for the modality.”

This is a notable win for mRNA technology beyond COVID-19. GSK’s success could accelerate Moderna and other mRNA players’ flu programs and validate the platform for seasonal vaccines—a multi-billion-dollar market opportunity.

MFN Drug Pricing: Nine New Deals

The White House unveiled nine new most-favored-nation drug pricing deals, this time targeting midsize biotechs (Endpoints News, Fierce Pharma, BioSpace). The deals follow the earlier rounds that focused on large pharma and represent the administration’s continued pressure on drug pricing.

Endpoints reports that the nine companies are primarily midsize players, suggesting the MFN program is broadening its reach. Fierce Pharma notes the White House is “unveiling the next round” of deals, framing it as an ongoing process rather than a one-time event. The policy landscape for drug pricing remains fluid, with industry groups continuing to challenge the program in court.

Novartis’ Rhapsido: Clean Phase 3 MS Data

Novartis received good news to offset the CAR-T setback: its BTK inhibitor Rhapsido (remibrutinib) cleared Phase 3 in multiple sclerosis without the liver safety signals that have plagued competitors (Fierce Pharma, Endpoints News). Endpoints reports that Rhapsido appears “safer than rivals,” a significant differentiator in the MS market where liver toxicity has been a concern for other BTK inhibitors.

This positions Novartis strongly in the competitive MS landscape, where Sanofi, Roche, and others are also advancing BTK programs. The clean safety profile could accelerate regulatory filings and give Novartis a first-mover advantage.

Alumis’ TYK2 Setback in Lupus

Alumis’ TYK2 inhibitor failed a midstage lupus study, sending shares down (Endpoints News, Fierce Biotech). However, the CEO sees a “clear path forward,” suggesting the company may pursue alternative indications or dose optimization. The lupus failure is a setback but not necessarily fatal for the TYK2 program, which has shown promise in other autoimmune conditions.

ArsenalBio’s Painful Pivot

ArsenalBio is shedding the “majority” of its staff as it pivots from ex vivo to in vivo CAR-T (BioSpace, Fierce Biotech). The move reflects a broader industry trend toward in vivo approaches, which avoid the complex manufacturing and logistics of ex vivo cell therapies. However, the human cost is significant—this is one of the more dramatic workforce reductions in recent biotech memory.

Deals, IPOs, and Corporate Moves

• ARCH Venture Partners is targeting a $3 billion raise for its latest fund (Endpoints News), signaling continued VC appetite for life sciences despite the challenging funding environment.
• Electra Therapeutics aims to IPO on Nasdaq to fund a Phase 2/3 immunology push (Fierce Biotech).
• BioMarin and Ascendis settled their achondroplasia patent dispute, with Ascendis paying 20% royalties (Fierce Pharma, BioSpace).
• Lonza appointed a returning executive as its new commercial chief (Fierce Pharma).
• K Health is eyeing an IPO by 2029 (Endpoints News).
• Lilly’s dealmaking is spreading wealth among a broad set of biotech venture investors (Endpoints News).

Clinical and Regulatory Notes

• AstraZeneca’s heart failure drug showed promise in a Phase 2 trial (Fierce Biotech).
• FDA dinged Alar over “extremely concerning” ketamine claims (Fierce Pharma).
• Stryker introduced the first FDA-authorized surgical application for Apple Vision Pro (PR Newswire).
• Medibyt received FDA 510(k) clearance for CPETWise (PR Newswire).
• Veeva announced Falcon Safety will work with all E2B-compliant safety systems (PR Newswire).
• Ultra Violette became the first US brand to launch sunscreen with newly FDA-approved filter bemotrizinol (PR Newswire).

What This Batch Is Not Telling Us

Today’s harvest is light on AI-in-bio stories, rare disease gene therapy news, and CDMO consolidation—areas that have been active in recent weeks. The CAR-T safety story dominates the narrative and may overshadow other developments for days to come. No China biotech security risk pieces today, despite the Roche-Simcere deals being China-focused.

Reading Order

For limited-time readers, the top five signals today:

1. CAR-T safety crisis — three deaths halt Novartis and BMS autoimmune trials; the modality’s biggest setback yet (Endpoints, Fierce Biotech, BioSpace)
2. Roche-Simcere $1.53B deal — Western pharma’s China biotech appetite remains strong (Fierce Biotech, Endpoints)
3. GSK mRNA flu vaccine Phase 3 — mRNA beyond COVID gets a major validation (Fierce Biotech, Endpoints, BioSpace)
4. Novartis Rhapsido clean MS data — BTK inhibitor without liver signals positions Novartis ahead (Fierce Pharma, Endpoints)
5. MFN drug pricing expands — nine new midsize biotech deals signal broadening policy pressure (Endpoints, Fierce Pharma)

Sources

All articles sourced from the daily biopharma news harvest, 2026-09-01. Full sourceUrls available in src/content/news/ frontmatter.